Familial combined hyperlipidemia in children: Clinical expression, metabolic defects, and management*

https://doi.org/10.1016/S0022-3476(05)81686-5Get rights and content

Familial combined hyperlipidemia (FCHL) is a dominantly inherited hyperlipidemia that occurs in at least 1% of the adult population and is responsible for 10% of premature coronary artery disease. In families referred for evaluation because of primary hyperlipidemia in a child, FCHL is expressed three times more commonly than familial hypercholesterolemia and half of the siblings are affected. Several metabolic defects apparently are associated with the FCHL phenotype. Most commonly, excess production of very low density lipoprotein apolipoprotein B can be demonstrated. In other families, reduced lipoprotein lipase activity is associated. One allele at a locus influencing apolipoprotein B levels predicts FCHL in a large proportion of families ascertained through affected children. Whether this allele is responsible for the excess of very low density lipoprotein apolipoprotein B detected in metabolic studies has not been elucidated. Management of FCHL in children begins with dietary modification. A bile acid sequestrant may be considered as well if diet cannot reduce the plasma low-density lipoprotein cholesterol level to less than 4.13 mmol/L (160 mg/dl) after the age of 10 years. Although the hydroxymethylglutaryl-coenzyme A reductase inhibitors are not currently recommended for children younger than 19 years of age, we speculate that they will be increasingly utilized for the management of FCHL in teenage boys who continue to have low density lipoprotein cholesterol levels greater than 4.13 mmol/L (160 mg/dl) after dietary modification.

References (59)

  • WestRJ et al.

    Long-term follow-up of children with familial hypercholesterolemia treated with cholestyramine

    Lancet

    (1980)
  • GrundySM et al.

    Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia

    J Lipid Res

    (1985)
  • AradY et al.

    Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production

    J Lipid Res

    (1990)
  • AradY et al.

    Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins

    Metabolism

    (1992)
  • NewmanWP et al.

    Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study

    N Engl J Med

    (1986)
  • Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking

    JAMA

    (1990)
  • GoldsteinJL et al.

    Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction

    J Clin Invest

    (1973)
  • GoldsteinJL et al.

    Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

    J Clin Invest

    (1973)
  • GrundySM et al.

    Familial Combined Hyperlipidemia Workshop

    Arteriosclerosis

    (1987)
  • KwiterovichPO

    Biochemical, clinical, genetic and metabolic studies of hyperapo-β-lipoproteinaemia

    J Inher Metab Dis

    (1988)
  • SnidermanAD et al.

    Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human low density [beta] lipoproteins)

    Proc Natl Acad Sci USA

    (1980)
  • HaydenMR et al.

    DNA polymorphisms in and around the apo-AI-CIII gene and genetic hyperlipidemias

    Am J Hum Genet

    (1987)
  • WojciechowskiA et al.

    Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23–q24

    Nature

    (1991)
  • WijsmanEM et al.

    Evidence against linkage of familial combined hyperlipidemia to the AI-CIII-AIV gene complex

    Circulation

    (1992)
  • HasstedtSJ et al.

    Major locus inheritance of apolipoprotein B in Utah pedigrees

    Genet Epidemiol

    (1987)
  • AmosCI et al.

    Linkage and segregation analyses of apolipoproteins A-1 and B, and lipoprotein cholesterol levels in a large pedigree with excess coronary heart disease

    Genet Epidemiol

    (1987)
  • PairitzG et al.

    Sources of inter-individual variation in the quantitative levels of apolipoprotein B in pedigrees ascertained through a lipid clinic

    Am J Hum Genet

    (1988)
  • PairitzG et al.

    Increased frequency of an allele raising apolipoprotein B (apoB) in a sample enriched for familial combined hyperlipidemia (FCH)

    Am J Hum Genet

    (1991)
  • Cited by (39)

    • Nutrition interventions for youth with dyslipidemia: a National Lipid Association clinical perspective

      2022, Journal of Clinical Lipidology
      Citation Excerpt :

      FCHL is one of the most common genetic causes of hyperlipidemia in the general population with an estimated prevalence of 0.5%−2.0%. Because of the peculiar variability of laboratory parameters and the frequent overlapping with the features of metabolic syndrome, FCHL is often not recognized nor appropriately treated in youth.37-38 Identifying FCHL during childhood can be difficult because of the lack of long-term data linking lipid values measured before age 12 to the expression of the disease in adulthood.

    • Hyperlipidemia in children

      2006, Thrombosis Research
    • Drug therapy of hyperlipidemia

      2003, Progress in Pediatric Cardiology
    View all citing articles on Scopus
    *

    Supported in part by grants HL-37435 and RR-00240 from the U.S. Public Health Service, National Institutes of Health, by a grant from the March of Dimes-Birth Defects Foundation (6-494), by a grant from the W. W. Smith Charitable Trust, and by a Nutrition Center Pilot Project grant supported by the Howard Heinz Endowment Fund.

    View full text